Hemophilia Market Snapshot: Long-Acting Products Poised To Transform Market
Executive Summary
The staid hemophilia market may soon see the introduction of long-acting factor products, reshuffling segment shares, moving patients to prophylactic use, and expanding an already substantial global market. Biogen will be first to market, followed by established players. But will the improvements be enough to sway providers and payers?
You may also be interested in...
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Ketamine May Shake Up The Treatment Of Major Depression
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.
The Disruptive Impact Of Retail Clinics
Retail health clinics are undergoing an intense period of partnering and business model change. Although the value proposition is rock solid, the real test will be whether clinics can offer complementary services to traditional primary care, and working with provider groups, help achieve the goal of population health management.